Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 20;39(24):2732-2733.
doi: 10.1200/JCO.21.00594. Epub 2021 May 27.

Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?

Affiliations
Comment

Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?

Anthony J Cmelak et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Robert L. FerrisStock and Other Ownership Interests: NovasentaConsulting or Advisory Role: Merck, Pfizer, EMD Serono, Numab, Macrogenics, Aduro Biotech, Novasenta, Sanofi, Zymeworks, Bristol Myers SquibbResearch Funding: Bristol Myers Squibb, AstraZeneca/MedImmune, Merck, Tesaro, Novasenta Tanguy SeiwartHonoraria: Merck, Bristol Myers Squibb, AstraZenecaConsulting or Advisory Role: Merck, Bristol Myers Squibb, Aduro Biotech, AstraZeneca, Bayer, Roche Molecular Diagnostics, Nanobiotix, Innate Pharma, CelgeneResearch Funding: Merck, Bristol Myers Squibb, Jounce TherapeuticsTravel, Accommodations, Expenses: Merck, Bristol Myers Squibb, Bayer, Roche Molecular Diagnostics, AstraZeneca, Celgene, Innate Pharma, Nanobiotix Barbara BurtnessConsulting or Advisory Role: Merck, Debiopharm Group, Aduro Biotech, Celgene, CUE Biopharma, Maverick Therapeutics, Rakuten Medical, Nanobiotix, Macrogenics, ALX Oncology, Oncolys BioPharma, IO Biotech, IpsenResearch Funding: Merck, Aduro Biotech, Formation Biologics, Bristol Myers, Exelixis, CUE BiopharmaTravel, Accommodations, Expenses: Merck, Debiopharm GroupNo other potential conflicts of interest were reported.

Comment in

  • Reply to A. J. Cmelak et al and B. Kalra et al.
    Yom SS, Torres-Saavedra PA, Le QT. Yom SS, et al. J Clin Oncol. 2021 Aug 20;39(24):2734-2735. doi: 10.1200/JCO.21.00882. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043429 No abstract available.
  • Reply to A. J. Cmelak et al and B. Kalra et al.
    Chundury A, Cosper PF, Kim S. Chundury A, et al. J Clin Oncol. 2021 Aug 20;39(24):2735-2736. doi: 10.1200/JCO.21.00885. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043438 No abstract available.

Comment on

  • Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Yom SS, et al. J Clin Oncol. 2021 Mar 20;39(9):956-965. doi: 10.1200/JCO.20.03128. Epub 2021 Jan 28. J Clin Oncol. 2021. PMID: 33507809 Free PMC article. Clinical Trial.

MeSH terms

LinkOut - more resources